Peking University Cancer Hospital
北京大学肿瘤医院
Listed for 10 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
Official links opened and checked on 2026-11-08.
Research at Peking University Cancer Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌2 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌82 papers led6 open trials led
- Hepatocellular carcinoma肝细胞癌42 papers led5 open trials led
- Stomach cancer胃癌223 papers led9 open trials led
- Osteosarcoma骨肉瘤4 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤12 papers led1 open trial led
- Neuroblastoma神经母细胞瘤1 paper led
- Ewing sarcoma尤文肉瘤2 papers led
- Multiple myeloma多发性骨髓瘤3 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 2 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.08%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Beijing for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma
No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
- Distribution of regional lymph nodes metastasis in 870 cases of nasopharyngeal carcinoma and the suggestions for individualized elective prophylactic neck irradiation with intensity-modulated radiotherapy.
- GLIM Criteria-Defined Malnutrition Informs on Survival of Nasopharyngeal Carcinoma Patients Undergoing Radiotherapy.
All its trials on ClinicalTrials.gov, any status7
- A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
- PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
- A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma
- Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma
- Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
More papers found outside PubMed (not counted)9
- PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized
- Impact of Radiotherapy on Radiation-Induced Brain Injury in Patients with Nasopharyngeal Carcinoma Using Nano-Magnetic Resonance Imaging
- 3D reconstruction-oriented fully automatic multi-modal tumor segmentation by dual attention-guided VNet
- Clinical Evaluation of AI-Assisted Virtual Contrast Enhanced MRI in Primary Gross Tumor Volume Delineation for Radiotherapy of Nasopharyngeal Carcinoma
- Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.
- Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study.
- 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results
- MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
- Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 82 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 2.8%.
13 hospitals in Beijing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
Open trials with this hospital 17
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
- Phase
- Phase 2
- Started
- 2025-03
- Registry
- NCT06869213
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingQL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-09
- Registry
- NCT07049185
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing
- RecruitingStudy of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-11
- Registry
- NCT06684600
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingRisk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery
- Phase
- Not given
- Started
- 2026-10
- Registry
- NCT07822906
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingPembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2022-12
- Registry
- NCT05386056
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Enrolling by invitationNimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07312578
Age 18 years to 70 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Registry
- NCT07405151
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Hangzhou, Hefei, Jinan, Xiamen, Xuzhou, Zhengzhou
- RecruitingQLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07463573
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
- Phase
- Phase 2/Phase 3
- Started
- 2026-06
- Registry
- NCT07554456
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingComparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
- Phase
- Phase 2
- Started
- 2026-07
- Registry
- NCT07733830
Age 18 years to 75 years (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Shenyang, Taiyuan, Tianjin, Zhengzhou
- RecruitingA Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-09
- Registry
- NCT07751341
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Zhengzhou
- RecruitingA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Phase
- Phase 3
- Started
- 2025-03
- Registry
- NCT06644781
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou
- RecruitingSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Registry
- NCT06780111
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Hefei, Nanchang, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Registry
- NCT06465069
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- Phase
- Phase 1/Phase 2
- Started
- 2023-05
- Registry
- NCT05319730
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Hangzhou, Hefei, Shanghai, Xiamen, Xinxiang, Zhengzhou
- RecruitingA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2022-10
- Registry
- NCT05208762
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- Not yet recruitingA Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07623642
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led82
- Extremely early genomic events and temporal order of esophageal squamous cell carcinogenesis: Longitudinal self-comparison of progressors and non-progressors.
- Establishment of a Chinese library of patient-derived xenografts from gastrointestinal cancers.
- Expression of kinetochore component NDC80 promotes esophageal squamous cell carcinoma cells proliferation and migration.
- Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers.
- Absolute Risk Prediction for Esophageal Squamous Cell Carcinoma Adaptable to Regional Disease Burden across Diverse Regions.
- An integrated prognosis prediction model based on real-word clinical characteristics for immunotherapy in advanced esophageal squamous cell carcinoma.
- PAF signaling axis functions as biomarker or target for esophageal squamous cell carcinoma diagnosis or treatment.
- Identification and characterization of Bufalin as a novel EGFR degrader.
- SQLE amplification accelerates esophageal squamous cell carcinoma tumorigenesis and metastasis through oncometabolite 2,3-oxidosqualene repressing Hippo pathway.
- An Image-Based Model for Assisting in Diagnosing Malignant Esophageal Lesions During Lugol Chromoendoscopic Examination.
- Persistence of Lugol-unstaining Is Associated With an Increased Risk of Progression to Malignancy in the Esophagus.
- Prognostic impact of recurrent laryngeal nerve lymph node metastatic status in thoracic esophageal squamous cell carcinoma.
- Integrating tumour and lymph node radiomics features for predicting disease-free survival in locally advanced esophageal squamous cell cancer after neoadjuvant chemotherapy and complete resection.
- NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.
- Integrative analysis of T cell-mediated tumor killing-related genes reveals KIF11 as a novel therapeutic target in esophageal squamous cell carcinoma.
- Harnessing the FGFR2/NF2/YAP signaling-dependent necroptosis to develop an FGFR2/IL-8 dual blockade therapeutic strategy.
- A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial.
- Focal adhesion kinase/Src family kinase axis-mediated tyrosine phosphorylation of metabolic enzymes facilitates tumor metastasis.
- Treatment choices after endoscopic resection for pMM/SM1 esophageal squamous cell cancer: a retrospective study in China.
- METTL3-mediated upregulation of FAM135B promotes EMT of esophageal squamous cell carcinoma via regulating the Wnt/β-catenin pathway.
- Early Contrast-Enhanced MR for Diagnosing Complete Tumor Response of Locally Advanced Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy: A Retrospective Comparative Study.
- ASO Author Reflections: The Challenging Journey from cCR to pCR After Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma.
- Long-Term Survival and Recurrence Patterns in Locally Advanced Esophageal Squamous Cell Carcinoma Patients with Pathologic Complete Response After Neoadjuvant Chemotherapy Followed by Surgery.
- Exploration of lymph node recurrence patterns and delineation guidelines of radiation field in middle thoracic oesophageal carcinomas after radical surgery: a real-world study.
- IGH repertoire analysis at scale: deciphering the complexity of B cell infiltration and migration in esophageal squamous cell carcinoma.
- Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.
- Somatic CDKN2A copy number variations are associated with the prognosis of esophageal squamous cell dysplasia.
- Tumor-associated macrophage (TAM)-secreted CCL22 confers cisplatin resistance of esophageal squamous cell carcinoma (ESCC) cells via regulating the activity of diacylglycerol kinase α (DGKα)/NOX4 axis.
- LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma.
- Leveraging new methods for comprehensive characterization of mitochondrial DNA in esophageal squamous cell carcinoma.
- Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma.
- Surgical quality determines the long-term survival superiority of right over left thoracic esophagectomy for localized esophageal squamous cell carcinoma patients: a real-world multicenter study.
- Genome-Scale Multimodal Analysis of Cell-Free DNA Whole-Methylome Sequencing for Noninvasive Esophageal Cancer Detection.
- Effectiveness of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: A 9-Year Report of the Endoscopic Screening for Esophageal Cancer in China (ESECC) Randomized Trial.
- Co-targeting TMEM16A with a novel monoclonal antibody and EGFR with Cetuximab inhibits the growth and metastasis of esophageal squamous cell carcinoma.
- Community prevention and standardized clinical treatment jointly improve cancer outcome: Real-world evidence from an esophageal cancer patient cohort study.
- miR-378a-5p exerts tumor-suppressive effects on esophageal squamous cell carcinoma after neoadjuvant immunotherapy by downregulating APOC1/CEP55.
- Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma.
- AKT2S128/CCTαS315/319/323-positive cancer-associated fibroblasts (CAFs) mediate focal adhesion kinase (FAK) inhibitors resistance via secreting phosphatidylcholines (PCs).
- Exploration of the pattern of lymph node metastasis in esophageal cancer based on membrane anatomy theory.
- Long noncoding RNA LINC01088 inhibits esophageal squamous cell carcinoma progression by targeting the NPM1-HDM2-p53 axis.
- Minimally Invasive or Open Esophagectomy for Treatment of Resectable Esophageal Squamous Cell Carcinoma? Answer From a Real-world Multicenter Study.
- Is Adjuvant Therapy a Better Option for Esophageal Squamous Cell Carcinoma Patients Treated With Esophagectomy? A Prognosis Prediction Model Based on Multicenter Real-World Data.
- CT radiomics features of meso-esophageal fat in predicting overall survival of patients with locally advanced esophageal squamous cell carcinoma treated by definitive chemoradiotherapy.
- A CT-Based Radiomics Nomogram Model for Differentiating Primary Malignant Melanoma of the Esophagus from Esophageal Squamous Cell Carcinoma.
- Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma.
- Combined Wee1 and EGFR inhibition reveals synergistic antitumor effect in esophageal squamous cell carcinoma.
- Absence of Lugol staining indicates initiation of esophageal squamous cell carcinoma: A combined genomic and epidemiologic study.
- Quantitative CT evaluation after two cycles of induction chemotherapy to predict prognosis of patients with locally advanced oesophageal squamous cell carcinoma before undergoing definitive chemoradiotherapy/radiotherapy.
- High-Dose Versus Standard-Dose Intensity-Modulated Radiotherapy With Concurrent Paclitaxel Plus Carboplatin for Patients With Thoracic Esophageal Squamous Cell Carcinoma: A Randomized, Multicenter, Open-Label, Phase 3 Superiority Trial.
- Lugol-unstained lesions location in the esophagus affects the detection rate of malignancy: a population-based study.
- Efficacy and Safety Profile of PD-1 Inhibitors Versus Chemotherapy in the Second-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Src heterodimerically activates Lyn or Fyn to serve as targets for the diagnosis and treatment of esophageal squamous cell carcinoma.
- CDK7-YAP-LDHD axis promotes D-lactate elimination and ferroptosis defense to support cancer stem cell-like properties.
- Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
- Primary malignant melanoma of the esophagus: differentiation from esophageal squamous cell carcinoma and leiomyoma using dynamic contrast-enhanced CT findings.
- Response to Comment on: "Is Adjuvant Therapy a Better Option for Esophageal Squamous Cell Carcinoma Patients Treated With Esophagectomy? A Prognosis Prediction Model Based on Multicenter Real-world Data".
- Combined Mean Corpuscular Hemoglobin, Fibrinogen, and Albumin (MF-A) Is a Novel Prognostic Marker in Patients with Resectable Esophageal Squamous Cell Carcinoma.
- Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
- Tumor-associated macrophage (TAM)-derived CCL22 induces FAK addiction in esophageal squamous cell carcinoma (ESCC).
- Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.
- The m6A-induced lncRNA CASC8 promotes proliferation and chemoresistance via upregulation of hnRNPL in esophageal squamous cell carcinoma.
- Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
- Characterization of somatic structural variations in 528 Chinese individuals with Esophageal squamous cell carcinoma.
- Postoperative lymphatic recurrence distribution and delineation of the radiation field in lower thoracic squamous cell esophageal carcinomas: a real-world study.
- Nuclear genome-derived circular RNA circPUM1 localizes in mitochondria and regulates oxidative phosphorylation in esophageal squamous cell carcinoma.
- Absence of NOTCH1 mutation and presence of CDKN2A deletion predict progression of esophageal lesions.
- Commentary: Endoscopic treatment is the key for superficial esophageal squamous cell neoplasia.
- Association between polymorphisms of ABCB1 and prognosis in esophageal squamous cell carcinoma patients treated with taxane.
- The metabolic genomic atlas reveals potential drivers and clinically relevant insights into the etiology of esophageal squamous cell carcinoma.
- MAGE-C3 promotes cancer metastasis by inducing epithelial-mesenchymal transition and immunosuppression in esophageal squamous cell carcinoma.
- BAALC-AS1/G3BP2/c-Myc feedback loop promotes cell proliferation in esophageal squamous cell carcinoma.
- Conditional survival in patients with esophageal or gastroesophageal junction cancer after receiving various treatment modalities.
- NOX5 mediates the crosstalk between tumor cells and cancer-associated fibroblasts via regulating cytokine network.
- Tumor-associated autoantibodies in ESCC screening: Detecting prevalent early-stage malignancy or predicting future cancer risk?
- RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.
- Polymorphism of FGD4 and myelosuppression in patients with esophageal squamous cell carcinoma.
- Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
- Genomic and epigenomic evolution of acquired resistance to combination therapy in esophageal squamous cell carcinoma.
- Predicting Lymph Node Metastasis Using Computed Tomography Radiomics Analysis in Patients With Resectable Esophageal Squamous Cell Carcinoma.
- Feed-forward activation of STAT3 signaling limits the efficacy of c-Met inhibitors in esophageal squamous cell carcinoma (ESCC) treatment.
- MXD1 is a Potential Prognostic Biomarker and Correlated With Specific Molecular Change and Tumor Microenvironment Feature in Esophageal Squamous Cell Carcinoma.
All its trials on ClinicalTrials.gov, any status59
- Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery
- A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
- QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma
- Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer
- HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma
- Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal Lesions
- Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal Carcinoma
- Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell Carcinoma
- Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
- Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
- Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma
- Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer
- To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC
- Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
- JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy
- The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
- Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification
- Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
- Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo)
- Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)
- Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System
- Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma
- Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma
- Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma
- Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer
- Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma
- Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.
- Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer
- Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer
- Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)
- Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
- QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
- A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
- A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
- JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
- A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
- A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
- A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
- Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma
- Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma
- Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma
- A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma
More papers found outside PubMed (not counted)62
- 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma
- 474TiP IDeate-Esophageal01: A phase III, randomized, open-label study of ifinatamab deruxtecan (I-DXd) in patients (pts) with pretreated advanced/metastatic esophageal squamous cell carcinoma (ESCC)
- 67eP ACR246, a novel 5T4 antibody-drug conjugate, showed promising anticancer efficacy in esophageal squamous cell carcinoma
- 963P SC-101, a Nectin-4-targeting peptide-drug conjugate (PDC), in patients (pts) with advanced or metastatic solid tumors: Results from dose escalation study
- A multi-epitope mRNA vaccine for effective immunotherapy in esophageal squamous cell carcinoma.
- Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and overall survival (OS) by programmed death-ligand 1 (PD-L1) expression in advanced or metastatic esophageal squamous cell carcinoma (ESCC):
- KEYMAKER-U06 substudy 06E: A phase 1/2 open-label, umbrella platform study of ifinatamab deruxtecan in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma (ESCC
- LBA79 Lenvatinib plus pembrolizumab and chemotherapy vs pembrolizumab and chemotherapy in untreated metastatic esophageal squamous cell carcinoma: The randomized phase III LEAP-014 study
- PT2.10.03 Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study
- Perioperative adebrelimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: A single-arm, open-label, multicenter study.
- The lost evidence: A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA–IIIB esophageal squamous cell carcinoma.
- 1426P BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)
- 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies
- 265TiP Phase I/II open-label, umbrella platform designed study of investigational agents with or without pembrolizumab and/or chemotherapy in patients with advanced esophageal cancer previously treated with a PD-(L)1 inhibitor: KEYMAKER-U06
- Abstract CT209: Camrelizumab plus chemotherapy as neoadjuvant treatment for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC): A single-center, randomized, phase II trial
- Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC).
- Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.
- Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial
- Octadecyl Gallate and Lipid‐Modified MnSe2 Nanoparticles Enhance Radiosensitivity in Esophageal Squamous Cell Carcinoma and Promote Radioprotection in Normal Tissues (Adv. Mater. 23/2024)
- Real-world data of anlotinib for gastrointestinal tumors with liver metastases in China.
- SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC).
- Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer.
- 1534P First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (mESCC): Safety run-in results from the phase III LEAP-014 study
- 189P Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
- Abstract CT075: Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-
- Abstract CT076: Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis
- Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Data from Long Noncoding RNA VESTAR Regulates Lymphangiogenesis and Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma by Enhancing VEGFC mRNA Stability
- Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).
- MO19-4 Impact of tislelizumab on health-related quality of life in Asian patients with esophageal squamous cell carcinoma
- 1207P Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study
- 70O Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup
- 80P RATIONALE-302: Tislelizumab vs chemotherapy as second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC): Impact on health-related quality of life (HRQoL) in Asian patients
- ASO Visual Abstract: Combined Mean Corpuscular Hemoglobin, Fibrinogen, and Albumin (MF-A) Is a Novel Prognostic Marker in Patients with Resectable Esophageal Squamous Cell Carcinoma
- Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF1
- First-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress.
- First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.
- LEAP-014: An open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma.
- Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an
- P-298 Open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress
- Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.
- Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.
- Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).
- Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).
- 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)
- 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm pha
- Comparison of Two Major Staging Systems in Predicting Survival and Recommendation of Postoperative Radiotherapy Based on the 11th Japanese Classification for Esophageal Carcinoma After Curative Resection
- Determining an Evidence-Based Surveillance Target and Respective Intervals for Esophageal Squamous Cell Carcinoma Following Screening: A Population-Based Cohort Study in China
- ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).
- First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.
- Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.
- LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study
- LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling
- O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup
- RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.
Cancer
Hepatocellular carcinoma
肝细胞癌Led 42 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.
17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 11
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingPhase I Study of OriC902 in Treatment of Advanced HCC
- Phase
- Phase 1
- Started
- 2025-02
- Registry
- NCT06891742
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing
- RecruitingAnti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
- Phase
- Phase 2
- Started
- 2024-01
- Registry
- NCT06360042
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingMts105 for Advanced Hepatocellular Carcinoma
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06689540
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingPhase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
- Phase
- Phase 2
- Started
- 2023-06
- Registry
- NCT05917431
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingSBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma
- Phase
- Phase 2
- Started
- 2026-10
- Registry
- NCT07882056
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingStudy of GV20-0251 in Participants With Solid Tumor Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Registry
- NCT07070518
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
- RecruitingA Study of DEG6498 in Participants With Solid Tumors
- Phase
- Phase 1
- Started
- 2025-11
- Registry
- NCT07244835
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou
- RecruitingTo Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07594964
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
- RecruitingA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2022-10
- Registry
- NCT05208762
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingOri-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Registry
- NCT05652920
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Hangzhou, Shanghai
- Not yet recruitingA Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07583316
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led42
- Negative 68Ga-FAPI-04 Uptake on PET/CT in HNF-1α-mutated Hepatocellular Adenoma: A Distinctive Feature for Differentiating From Hepatocellular Carcinoma.
- Radiotherapy combined with anti-PD-1 immunotherapy promotes ferroptosis-driven control of hepatocellular carcinoma.
- Effect of AFP and PIVKA-II secretion status on prognosis of advanced hepatocellular carcinoma patients receiving TACE combined with systemic therapy.
- Identification of Key Genes and Pathways in Lenvatinib-resistant Hepatocellular Carcinoma using Bioinformatic Analysis and Experimental Validation.
- SIRT4 Controls Acetyl-CoA Synthesis to Promote Stemness and Invasiveness of Hepatocellular Carcinoma through Deacetylating MCCC2.
- Long non-coding RNA LINC01532 sustains redox homeostasis and accelerates lenvatinib resistance in hepatocellular carcinoma.
- The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial.
- PFDN6L Gene Predicts Good Prognosis Associated with Its Inhibition of the Stem-Ness Properties in Hepatocellular Carcinoma.
- Targeting NETO2 suppresses cell proliferation, invasion, and migration and inactivates the STAT3/C-MYC pathway in hepatocellular carcinoma.
- Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial.
- GSTA1/CTNNB1 axis facilitates sorafenib resistance via suppressing ferroptosis in hepatocellular carcinoma.
- A novel nomogram for prediction of intrahepatic recurrence-free survival in patients with HCC followed by radiofrequency ablation.
- Multimode Ultrasound Model for Predicting the Early Treatment Response of Anti-VEGF Agents Plus Anti-PD-1 Antibody in Patients with Unresectable Hepatocellular Carcinoma.
- Evaluation of the Time Difference Method in Identifying Hepatocellular Carcinoma in Current CEUS LR-M Category Nodules.
- Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma.
- Effect of vessels that encapsulate tumor clusters (VETC) on the prognosis of different stages of hepatocellular carcinoma after hepatectomy.
- An evaluation of 20-year survival of radiofrequency ablation for hepatocellular carcinoma as first-line treatment.
- Evaluation of the safety and efficacy of ultrasound-guided percutaneous radiofrequency ablation for hepatocellular carcinoma and liver metastases adjacent to the gallbladder.
- Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.
- Activation of ACLY by SEC63 deploys metabolic reprogramming to facilitate hepatocellular carcinoma metastasis upon endoplasmic reticulum stress.
- Survival benefit of radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma: A propensity score-matched analysis based on phase II study.
- Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
- Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma.
- Liver tumor-initiating cells initiate the formation of a stiff cancer stem cell microenvironment niche by secreting LOX.
- A nomogram based on a three pyroptosis gene model and clinical parameters for predicting prognosis of hepatocellular carcinoma.
- Diagnostic value of color parametric imaging and contrast-enhanced ultrasound in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma.
- PPP1R26 drives hepatocellular carcinoma progression by controlling glycolysis and epithelial-mesenchymal transition.
- Prognostic significance of albumin-bilirubin score in patients with unresectable hepatocellular carcinoma undergoing combined immunotherapy and radiotherapy.
- Hepatic Artery Injection of 131I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical Trial.
- CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma.
- Long non‑coding RNA LINC00238 suppresses the malignant phenotype of liver cancer by sponging miR‑522.
- Long noncoding RNA LINC01234 promotes hepatocellular carcinoma progression through orchestrating aspartate metabolic reprogramming.
- A Multicenter Randomized Controlled Study of Contrast-enhanced US versus US-guided Biopsy of Focal Liver Lesions.
- Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial.
- Computer-Aided Color Parameter Imaging of Contrast-Enhanced Ultrasound Evaluates Hepatocellular Carcinoma Hemodynamic Features and Predicts Radiofrequency Ablation Outcome.
- Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
- The effect of propofol on the proliferation and apoptosis of hepatocellular carcinoma cells through TGF-Β1/Smad2 signaling pathway.
- Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance.
- Epidemiology of Alcohol-Associated Liver Disease.
- Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
- γ-Glutamyltranspeptidase as a Prognostic Biomarker in Advanced Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
- The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status50
- SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma
- Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
- Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
- The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma
- The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma
- Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection
- A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients
- The Effect of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma
- Phase I Study of OriC902 in Treatment of Advanced HCC
- Mts105 for Advanced Hepatocellular Carcinoma
- HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion
- Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
- Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma
- Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis
- A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC
- A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
- A Study of DEG6498 in Participants With Solid Tumors
- Study of GV20-0251 in Participants With Solid Tumor Malignancies
- To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
- A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC
- A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
- A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
- A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC
- A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
- Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
- A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
- A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
- A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
- A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
- Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
- A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
- Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
- Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
- A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
- The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
- Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry
- The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects
- STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
- Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
- Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
- Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
- T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients
Cancer
Stomach cancer
胃癌Led 223 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 2.3%.
15 hospitals in Beijing for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 42
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingctDNA-MRD Monitoring After Resection in Gastric Cancer
- Phase
- Not given
- Started
- 2025-04
- Registry
- NCT06893133
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingAssessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07127822
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Harbin, Qingdao, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou
- RecruitingNKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06134960
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingEffectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer
- Phase
- N/A
- Started
- 2024-06
- Registry
- NCT06306755
Age 50 years to 69 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingResearch on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization
- Phase
- N/A
- Started
- 2024-08
- Registry
- NCT06429891
Age 18 years to 70 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingImmune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
- Phase
- Phase 2
- Started
- 2024-09
- Registry
- NCT06580574
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingPhase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
- Phase
- Phase 2
- Started
- 2023-09
- Registry
- NCT06023758
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingPaclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
- Phase
- N/A
- Started
- 2019-09
- Registry
- NCT04047953
Age 18 years to 75 years (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingNon-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers
- Phase
- Not given
- Started
- 2026-06
- Registry
- NCT07656740
Age not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Phase
- Phase 2/Phase 3
- Started
- 2026-03
- Registry
- NCT07221149
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Nanning, Shanghai
- RecruitingA Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-01
- Registry
- NCT07315750
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Registry
- NCT07354711
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingLM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07362186
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07385703
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou
- RecruitingA Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07518147
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingClinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07522151
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingPhase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07700979
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingRadical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Phase
- Phase 3
- Started
- 2026-12
- Registry
- NCT07789184
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an
- RecruitingStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Registry
- NCT06731478
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou
- RecruitingA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Phase
- Phase 2
- Started
- 2025-02
- Registry
- NCT06760819
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai
- RecruitingBC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 1
- Started
- 2025-02
- Registry
- NCT06773312
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingReal-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06846996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou
- RecruitingSON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2025-02
- Registry
- NCT06873659
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan, Lanzhou, Nanjing, Shanghai, Xi'an
- RecruitingA Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
- Phase
- Phase 3
- Started
- 2025-08
- Registry
- NCT07023315
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Harbin, Shanghai, Shijiazhuang
- RecruitingA Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-07
- Registry
- NCT07066657
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Shanghai, Wuhan, Zhengzhou
- RecruitingAn Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-12
- Registry
- NCT07371663
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Zhengzhou
- RecruitingTo Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07594964
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
- RecruitingDV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- Phase
- Phase 2/Phase 3
- Started
- 2024-02
- Registry
- NCT06221748
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Harbin, Jinan, Kunming, Qingdao, Shanghai, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Registry
- NCT06469944
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Urumqi, Xiamen, Zhengzhou
- RecruitingA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- Phase
- Phase 3
- Started
- 2024-11
- Registry
- NCT06532006
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou
- RecruitingA Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT07547787
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingPrediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
- Phase
- Not given
- Started
- 2023-01
- Registry
- NCT05722275
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Kunming, Taiyuan, Zhengzhou
- RecruitingA Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
- Phase
- Phase 2
- Started
- 2023-11
- Registry
- NCT06008054
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingAI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- Phase
- Not given
- Started
- 2023-09
- Registry
- NCT06035250
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou
- RecruitingPerioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 2
- Started
- 2023-11
- Registry
- NCT06155383
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Jinan, Kunming, Xiamen, Zhengzhou
- RecruitingM108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2023-12
- Registry
- NCT06177041
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2022-01
- Registry
- NCT05150691
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
- RecruitingA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2022-10
- Registry
- NCT05208762
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingA Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
- Phase
- Phase 1
- Started
- 2022-02
- Registry
- NCT05262491
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Jinan, Nanchang, Tianjin
- RecruitingStudy of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2021-06
- Registry
- NCT04900818
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- Not yet recruitingA Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06944496
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingA PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
- Phase
- Phase 1
- Started
- 2024-11
- Registry
- NCT06614751
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led223
- Discordance in tumour response assessment for gastric cancer after neoadjuvant chemotherapy using different methods.
- Characterization of Microplastics in Human Gastric Cancer and Control Tissues and Analysis of Associated Genetic Features.
- TOPK Inhibition Promotes Anti-Tumor Immunity Via eIF4F Complex Mediated STAT1 Translation in Gastric Cancer.
- Impact of concomitant medications on efficacy of CLDN18.2-specific CAR-T cell therapy in advanced gastric cancer.
- Predicting 177Lu-DOTATATE therapy response through immune microenvironment parameters in gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
- Postoperative infectious complications in gastric and colorectal cancer patients: A multicenter prospective cohort study from China.
- Comparison of postoperative reflux esophagitis in different digestive tract reconstruction methods after proximal gastrectomy for proximal gastric cancer patients: a network meta-analysis and systematic review.
- Histological and biomarker landscape of Claudin18.2-positive gastric and gastroesophageal junction cancers: a study of 937 cases.
- A CLDN18.2-Targeted Nanoplatform Manipulates Magnetic Hyperthermia Spatiotemporally for Synergistic Immunotherapy in Gastric Cancer.
- Utilizing Combined Circulating Tumor DNA and Tumor Markers to Evaluate Neoadjuvant Therapy Response and Predict Recurrence in Patients with Locally Advanced Gastric Cancer.
- The value of translational therapy in the treatment of advanced hepatoid adenocarcinoma of stomach.
- Establishment of a Chinese library of patient-derived xenografts from gastrointestinal cancers.
- Clinicopathologic characteristics and prognostic factors of pure gastric neuroendocrine carcinoma patients undergoing radical surgery.
- Comprehensive evaluation of tumor response better evaluates the efficacy of neoadjuvant chemotherapy and predicts the prognosis in gastric cancer - a post hoc analysis of a single-center randomized controlled trial.
- Immune microenvironment spatial landscapes of tertiary lymphoid structures in gastric cancer.
- Comparison of the safety of esophagojejunal overlap and π-shaped anastomosis in totally laparoscopic total gastrectomy.
- Effect of risk-based screening for upper gastrointestinal cancers: a multi-center real-world study.
- Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer.
- Proteomic profiling and scRNA sequencing identify signatures associated with Helicobacter pylori infection and risk of developing gastric cancer.
- Plasma L-aspartic acid predicts the risk of gastric cancer and modifies the primary prevention effect: a multistage metabolomic profiling and Mendelian randomization study.
- Advances and challenges in gastric cancer testing: the role of biomarkers.
- Harnessing exosomes: From tumor immune escape to therapeutic innovation in gastric cancer immunotherapy.
- Hepatoid adenocarcinoma of the stomach and non-hepatoid alpha-fetoprotein-producing gastric cancer exhibit a high degree of molecular similarity.
- Feasibility and long-term survival of proximal gastrectomy after neoadjuvant therapy for locally advanced proximal gastric cancer: A propensity-score-matched analysis.
- Ginkgolide B Inhibits EMT and Promotes Pyroptosis in Gastric Cancer via AKT/mTOR Pathway.
- Integrating genetics and transcriptomics to decipher susceptibility genes for risk stratification of gastric cancer and effect modification of Helicobacter pylori treatment.
- Computed tomography features of gastric cancer with deficient mismatch repair: Radiologic-pathologic correlation.
- Identifying potential beneficiaries of neoadjuvant therapy in borrmann type III and IV gastric cancer: A treatment heterogeneity analysis using causal survival forests.
- CT radiomics-based intratumoral and intertumoral heterogeneity indicators for prognosis prediction in gastric cancer patients receiving neoadjuvant chemotherapy.
- Multi-omic profiling identifies KRT1 as a predictor of immune infiltration and prognosis in gastroesophageal junction cancer.
- Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancer.
- Host Genetic Variants Associated With Helicobacter pylori Infection: A Meta-Analysis Combined With Functional Annotation.
- Enhanced HER2 status detection in breast and gastric cancers using surrogate DNA methylation markers.
- Integrative metabolomics and microbiomics analysis reveals distinctive microbiota-metabolites interactions in gastric carcinogenesis.
- First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial.
- Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer: A Randomized Clinical Trial.
- Impact of Psychological Factors on Survival in Metastatic Esophagogastric Cancer: Secondary Analysis of a Randomized Controlled Trial.
- The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis.
- Short-term outcomes of robotic versus laparoscopic gastrectomy for proximal gastric cancer: a systematic review and meta-analysis of propensity score-matched or baseline-balanced retrospective studies.
- Laparoscopic vs robot-assisted gastrectomy in gastric cancer patients with prior abdominal surgery: a propensity-matched analysis.
- Serum miR-30c serves as potential biomarkers for the diagnosis and prognosis of gastric cancer.
- Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.
- Advances in the study of the role of gastric microbiota in the progression of gastric cancer.
- The accumulation of myeloid-derived suppressor cells participates in abdominal infection-induced tumor progression through the PD-L1/PD-1 axis.
- CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial.
- First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
- Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms and its potential diagnostic value.
- PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial.
- Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final re
- Noninvasive in vivo tracking of SPIONs-labeled CLDN18.2-targeted CAR-T cells in gastric cancer via magnetic particle imaging.
- Diagnostic accuracy of stereomicroscopy assessment of invasion depth in ex vivo specimens of early gastric cancer.
- Lymph node metastatic patterns of gastric carcinoma with a combination of adenocarcinoma and neuroendocrine carcinoma components.
- Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review.
- Pre- and Post-treatment Double-Sequential-Point Dynamic Radiomic Model in the Response Prediction of Gastric Cancer to Neoadjuvant Chemotherapy: 3-Year Survival Analysis.
- A modified esophagogastric reconstruction method after laparoscopic proximal gastrectomy: A technical note with video vignette.
- Long-term outcomes of laparoscopic versus open total gastrectomy in patients with advanced gastric cancer after neoadjuvant chemotherapy: a retrospective cohort study.
- Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer.
- Advances in MET tyrosine kinase inhibitors in gastric cancer.
- Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers.
- Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.
- Phase I study of BC001, a novel fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2, in advanced solid tumors.
- Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression.
- Exploration of molecular markers related to chemotherapy efficacy of hepatoid adenocarcinoma of the stomach.
- Development and external validation of a quantitative diagnostic model for malignant gastric lesions in clinical opportunistic screening: A multicenter real-world study.
- Single-cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis.
- ABCC2 induces metabolic vulnerability and cellular ferroptosis via enhanced glutathione efflux in gastric cancer.
- Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification.
- [177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models.
- MiRNA29a-3p negatively regulates ISL1-Integrin β1 axis to suppress gastric cancer progression.
- CDKN2A somatic copy number amplification in normal tissues surrounding gastric carcinoma reduces cancer metastasis risk in droplet digital PCR analysis.
- Specific lineage transition of tumor-associated macrophages elicits immune evasion of ascitic tumor cells in gastric cancer with peritoneal metastasis.
- Intratumoral microbiome is associated with gastric cancer prognosis and therapy efficacy.
- Tracking circulating PD-L1-positive cells to monitor the outcome of patients with gastric cancer receiving anti-HER2 plus anti-PD-1 therapy.
- Prevalence and detection methodology for preliminary exploration of NTRK fusion in gastric cancer from a single-center retrospective cohort.
- The tumor immune microenvironment remodeling and response to HER2-targeted therapy in HER2-positive advanced gastric cancer.
- A noninvasive multianalytical approach establishment for risk assessment and gastric cancer screening.
- Multiple approaches revealed MGc80-3 as a somatic hybrid with HeLa cells rather than a gastric cancer cell line.
- Helicobacter pylori Treatment and Gastric Cancer Risk Among Individuals With High Genetic Risk for Gastric Cancer.
- Dynamic change in the peritoneal cancer index based on CT after chemotherapy in the overall survival prediction of gastric cancer patients with peritoneal metastasis.
- Analyzing the associations between tertiary lymphoid structures and postoperative prognosis, along with immunotherapy response in gastric cancer: findings from pooled cohort studies.
- The deubiquitinase USP15 drives malignant progression of gastric cancer through glucose metabolism remodeling.
- Advanced Gastric Cancer: CT Radiomics Prediction of Lymph Modes Metastasis After Neoadjuvant Chemotherapy.
- Implications of PD-L1 expression on the immune microenvironment in HER2-positive gastric cancer.
- Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.
- Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial.
- Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data.
- Long-term outcomes of laparoscopic versus open distal gastrectomy for patients with advanced gastric cancer in North China: a multicenter randomized controlled trial.
- Risk factors and clinical significance of lower perigastric lymph node metastases in Siewert type II and III esophagogastric junction adenocarcinoma: a retrospective cohort study.
- Safety and short-term outcomes of a modified valvuloplastic esophagogastrostomy versus gastric tube anastomosis after laparoscopy-assisted proximal gastrectomy: a retrospective cohort study.
- Multi-regional sequencing reveals the genetic and immune heterogeneity of non-cancerous tissues in gastric cancer.
- Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases.
- Targeting SALL4 by Entinostat Inhibits the Malignant Phenotype of Gastric Cancer Cells by Reducing EMT Signaling.
- Prognostic significance of preoperative serum tumor markers in hepatoid adenocarcinoma of stomach (HAS).
- Analysis of enhanced CT imaging signs and clinicopathological prognostic factors in hepatoid adenocarcinoma of stomach patients with radical surgery: a retrospective study.
- Identification of Immunogenic Cell-Death-Related Subtypes and Development of a Prognostic Signature in Gastric Cancer.
- From intestinal metaplasia to gastric cancer: Witnessing the rise of evil over time and space.
- Kinase D-interacting Substrate of 220 kDa Is Overexpressed in Gastric Cancer and Associated With Local Invasion.
- Pulmonary lymphangitis carcinomatosis: A peculiar presentation clustering in MET-amplified gastric cancer.
- Tumor regression grade combined with post-therapy lymph node status: A novel independent prognostic factor for patients treated with neoadjuvant therapy followed by surgery in locally advanced gastroesophageal junction and gastric carcinoma
- T-cells infiltration mediates the association between neutrophil/lymphocyte ratio and survival in gastric cancer.
- Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results.
- Gastric cancer-associated long non-coding RNA profiling and noninvasive biomarker screening based on a high-risk population cohort.
- Pyrotinib alone or in combination with docetaxel in refractory HER2-positive gastric cancer: A dose-escalation phase I study.
- The N6-methyladenine DNA demethylase ALKBH1 promotes gastric carcinogenesis by disrupting NRF1 binding capacity.
- Next stage of collaboration in East Asia gastric cancer treatment.
- Global burden prediction of gastric cancer during demographic transition from 2020 to 2040.
- The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer.
- Multidimensional immune profiling in Gastric Cancer Multiplex Immunohistochemistry Atlas from Peking University Cancer Hospital project informs PD-1/PD-L1 blockade efficacy.
- First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection.
- Death receptor 5 promotes tumor progression in gastric cancer.
- Time to surgery does not affect oncologic outcomes in locally advanced gastric cancer after neoadjuvant chemotherapy: a meta-analysis.
- First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
- China special issue on gastrointestinal tumors-Improved survival after multidisciplinary team decision for patients with advanced gastrointestinal cancer: A multicenter, noninterventional, controlled study.
- Using Normalized Carcinoembryonic Antigen and Carbohydrate Antigen 19 to Predict and Monitor the Efficacy of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.
- Aspartate β-Hydroxylase Serves as a Prognostic Biomarker for Neoadjuvant Chemotherapy in Gastric Cancer.
- Long-term health-related quality of life in patients with gastric cancer after total or distal gastrectomy: a propensity score-matched cohort study.
- CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.
- Associations of subcutaneous fat area and Systemic Immune-inflammation Index with survival in patients with advanced gastric cancer receiving dual PD-1 and HER2 blockade.
- Discrimination of Liver Metastases of Digestive System Neuroendocrine Tumors From Neuroendocrine Carcinoma by Computed Tomography-Based Radiomics Analysis.
- Profiling of the genetic features of Chinese patients with gastric cancer with HRD germline mutations in a large-scale retrospective study.
- Efficacy and safety of preoperative immunotherapy alone followed by surgery in the treatment of advanced gastric cancer with MSI-H/dMMR or EBV-positive.
- Transcriptome profiling of patient-derived tumor xenografts suggests novel extracellular matrix-related signatures for gastric cancer prognosis prediction.
- Metabolite Alterations and Interactions with Microbiota in Helicobacter pylori-Associated Gastric Lesions.
- Label-free serum proteomics for the identification of the putative biomarkers of postoperative pain in patients with gastric cancer.
- Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer.
- Piceatannol enhances Beclin-1 activity to suppress tumor progression and its combination therapy strategy with everolimus in gastric cancer.
- TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance.
- Allium vegetable intake associated with the risk of incident gastric cancer: a continuous follow-up study of a randomized intervention trial.
- An exploration of gastric cancer with heterogeneous mismatch repair status.
- Prognostic nomograms for gastric carcinoma after D2 + total gastrectomy to assist decision-making for postoperative treatment: based on Lasso regression.
- Efficacy of chemotherapy versus surgery as initial treatment for gastric cancer with positive peritoneal cytology.
- Response to the rechallenge of combination immunotherapy in a patient with late-stage gastric cancer: case report.
- Early Diagnosis of Anastomotic Leakage After Gastric Cancer Surgery Via Analysis of Inflammatory Factors in Abdominal Drainage.
- Associations of Annual Hospital and Surgeon Volume with Patient Outcomes After Gastrectomy: A Systematic Review and Meta-analysis.
- Safety and short-term outcomes of gastrectomy after preoperative chemotherapy plus immunotherapy versus preoperative chemotherapy: a retrospective cohort study.
- The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study.
- A potential decision-making algorithm based on endoscopic ultrasound for staging early gastric cancer: a retrospective study.
- A 9‑gene expression signature to predict stage development in resectable stomach adenocarcinoma.
- Epstein-Barr virus-associated gastric adenosquamous carcinoma with concurrent gastric carcinoma with lymphoid stroma: a case report and review of the literature.
- Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial.
- Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.
- Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma.
- Clinical Significance and Immune Infiltration Analyses of the Cuproptosis-Related Human Copper Proteome in Gastric Cancer.
- Early detection of gastric cancer in China: progress and opportunities.
- SDCBP-AS1 destabilizes β-catenin by regulating ubiquitination and SUMOylation of hnRNP K to suppress gastric tumorigenicity and metastasis.
- Urine proteomic signatures predicting the progression from premalignancy to malignant gastric cancer.
- Beneficial effects of endoscopic screening on gastric cancer and optimal screening interval: a population-based study.
- Psychological distress and resilience in patients with gastroenteropancreatic neuroendocrine tumor.
- The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma.
- miRNAs derived from plasma small extracellular vesicles predict organo-tropic metastasis of gastric cancer.
- JAK-STAT1 Signaling Pathway Is an Early Response to Helicobacter pylori Infection and Contributes to Immune Escape and Gastric Carcinogenesis.
- Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis.
- Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
- Successful treatment of a case with synchronous follicular lymphoma and gastric adenocarcinoma with CD19 CAR T cells and literature review.
- Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer.
- Interpretable tumor differentiation grade and microsatellite instability recognition in gastric cancer using deep learning.
- Omitting nasogastric tube placement after gastrectomy does not enhance postoperative recovery: a propensity score matched analysis.
- A liquid biopsy signature of circulating exosome-derived mRNAs, miRNAs and lncRNAs predict therapeutic efficacy to neoadjuvant chemotherapy in patients with advanced gastric cancer.
- Targeting Claudin 18.2 Using a Highly Specific Antibody Enables Cancer Diagnosis and Guided Surgery.
- Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment.
- Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.
- Gamma-glutamyltransferase 7 suppresses gastric cancer by cooperating with RAB7 to induce mitophagy.
- Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer.
- Identification of Preoperative Serum Metabolites Associated With Postoperative Opioid Consumption in Gastric Cancer Patients by Extreme Phenotype Sampling.
- Dual roles of β-arrestin 1 in mediating cell metabolism and proliferation in gastric cancer.
- Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study.
- Modified π-shaped esophagojejunostomy in totally laparoscopic total gastrectomy: a report of 40 consecutive cases from a single center.
- Plasma lipids signify the progression of precancerous gastric lesions to gastric cancer: a prospective targeted lipidomics study.
- Feasibility of same-day discharge following endoscopic submucosal dissection for esophageal or gastric early cancer.
- Short-and long-term outcomes of laparoscopic versus open gastrectomy in patients with gastric cancer: a systematic review and meta-analysis of randomized controlled trials.
- Role of CT in the prediction of pathological complete response in gastric cancer after neoadjuvant chemotherapy.
- Utility of the gastric window in computed tomography for differentiation of early gastric cancer (T1 stage) from muscularis involvement (T2 stage).
- Ultrasensitive Gastric Cancer Circulating Tumor Cellular CLDN18.2 RNA Detection Based on a Molecular Beacon.
- Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy.
- Construction and Validation of a Risk-Scoring Model that Preoperatively Predicts Lymph Node Metastasis in Early Gastric Cancer Patients.
- Effect of Additional Trastuzumab in Neoadjuvant and Adjuvant Treatment for Patients with Resectable HER2-Positive Gastric Cancer.
- The T-Cell-Inflammation Status Can Predict Outcomes of Adjuvant Chemotherapy in Patients with Gastric Cancer.
- Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study.
- DNA methylation signatures associated with prognosis of gastric cancer.
- Phase II trial of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery.
- Combination of tumor markers predicts progression and pathological response in patients with locally advanced gastric cancer after neoadjuvant chemotherapy treatment.
- Development and validation of a novel staging system integrating the number and location of lymph nodes for gastric adenocarcinoma.
- Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.
- Insulin gene enhancer protein 1 mediates glycolysis and tumorigenesis of gastric cancer through regulating glucose transporter 4.
- Dysregulated KRAS gene-signaling axis and abnormal chromatin remodeling drive therapeutic resistance in heterogeneous-sized circulating tumor cells in gastric cancer patients.
- Clinicopathological features and lymph node and distant metastasis patterns in patients with gastroenteropancreatic mixed neuroendocrine-non-neuroendocrine neoplasm.
- Conditional survival in patients with esophageal or gastroesophageal junction cancer after receiving various treatment modalities.
- Double Tract Reconstruction Reduces Reflux Esophagitis and Improves Quality of Life after Radical Proximal Gastrectomy for Patients with Upper Gastric or Esophagogastric Adenocarcinoma.
- An Innovative Prognostic Model Based on Four Genes in Asian Patient with Gastric Cancer.
- EGR1-mediated linc01503 promotes cell cycle progression and tumorigenesis in gastric cancer.
- Comparison of neoadjuvant chemotherapy followed by surgery vs. surgery alone for locally advanced gastric cancer: a meta-analysis.
- Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
- Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
- Effect of administration of a proton pump inhibitor for ulcerative differentiated early gastric cancer prior to endoscopic submucosal dissection.
- Proteomic profiling identifies signatures associated with progression of precancerous gastric lesions and risk of early gastric cancer.
- Impact of 68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring.
- Could computed tomography be used as a surrogate of endoscopic ultrasonography in the screening and surveillance of small gastric Gastrointestinal stromal tumors?
- Comparison of totally laparoscopic and laparoscopic assisted gastrectomy after neoadjuvant chemotherapy in locally advanced gastric cancer.
- Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy.
- Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors.
- Deep learning system for lymph node quantification and metastatic cancer identification from whole-slide pathology images.
- ASB16-AS1 up-regulated and phosphorylated TRIM37 to activate NF-κB pathway and promote proliferation, stemness, and cisplatin resistance of gastric cancer.
- Profiling heterogenous sizes of circulating tumor microemboli to track therapeutic resistance and prognosis in advanced gastric cancer.
- CXCL16 Promotes Gastric Cancer Tumorigenesis via ADAM10-Dependent CXCL16/CXCR6 Axis and Activates Akt and MAPK Signaling Pathways.
- MicroRNA-135b/CAMK2D Axis Contribute to Malignant Progression of Gastric Cancer through EMT Process Remodeling.
- Identification and Validation of Plasma Metabolomic Signatures in Precancerous Gastric Lesions That Progress to Cancer.
- Effects of laparoscopic-assisted gastrectomy on elderly patients with gastric cancer.
- Surgical and oncological efficacy of laparoscopic-assisted total gastrectomy versus open total gastrectomy for gastric cancer by propensity score matching: a retrospective comparative study.
- Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial.
- Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
- Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
- Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
- Short-term outcomes after totally laparoscopic total gastrectomy with esophagojejunostomy constructed by π-shaped method versus overlap method.
- Comparison of the short-term outcomes of laparoscopic and open total or proximal gastrectomy using the transorally inserted anvil (OrVilTM) for the proximal reconstruction: a propensity score matching analysis.
- Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications.
- Association of serotonin transporter-linked polymorphic region (5-HTTLPR) with heat pain stimulation and postoperative pain in gastric cancer patients.
- Genomic and transcriptomic profiling of hepatoid adenocarcinoma of the stomach.
- Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer.
- Proteomics provides individualized options of precision medicine for patients with gastric cancer.
- Risk factors for esophagojejunal anastomotic leakage after curative total gastrectomy combined with D2 lymph node dissection for gastric cancer.
- Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-
- Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 t
- Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE).
Chinese-language papers (not in the count)20
- [Development and dissemination of precision medicine approaches in gastric cancer management].
- [Development status and prospects of functional preservation surgery for gastric cancer].
- [Precise diagnosis and treatment strategies for gastric cancer guided by clinical issues].
- [Tissue and plasma proteomic signatures associated with the risk of gastric cancer].
- [Surgical management of gastric cancer in the era of immunotherapy].
- [Analysis of the efficacy and safety of preoperative programmed death protein-1 inhibitor combined with chemotherapy in immunotherapy-sensitive patients with locally advanced gastric cancer or adenocarcinoma of the esophagogastric junction]
- [Neoadjuvant immunotherapy ushers in a new era of gastric cancer treatment].
- [Impact and intervention of postoperative complications after gastric cancer surgery from a health economics perspective].
- [Regarding the selection of individualized therapy after neoadjuvant therapy for gastrointestinal tumors].
- [Incidence of postoperative complications in Chinese patients with gastric or colorectal cancer based on a national, multicenter, prospective, cohort study].
- [Quality control in the establishment and management of gastric cancer database].
- [Interpretation on the report of global cancer statistics 2022].
- [Clinicopathological characteristics of gastric SMARCA4-deficient undifferentiated/rhabdoid carcinoma].
- [Building world leading surgical oncology for gastric cancer in China].
- [Surveys on diagnosis and treatment of esophagogastric junction adenocarcinoma by the Chinese Laparoscopic Gastrointestinal Surgery Study Group-10 Research Team].
- [The risk of incident gastric cancer for populations with different precancerous gastric lesions: a prospective follow-up study].
- [Dissection borders of laparoscopic lower mediastinal lymphadenectomy for adenocarcinoma of esophagogastric junction and the quality control].
- [Accurate diagnosis and individualized treatment of advanced gastric cancer: pathological detection of biomarkers based on cancer tissue samples].
- [Progress in gastric cancer with positive peritoneal cytology].
- [Implementation strategy of enhanced recovery after surgery in perioperative management of gastric cancer].
All its trials on ClinicalTrials.gov, any status147
- Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers
- Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer
- Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
- Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastric Adenocarcinoma
- Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
- Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for AGC
- Quality of Life in Advanced Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy
- Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer
- Molecular Evaluation of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
- Effect of Laparoscopy-Assisted Distal Gastrectomy for Locally Advanced Gastric Cancer
- DNA Methylation Biomarkers and Metastasis of Gastric Carcinoma
- Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis
- ctDNA-MRD Monitoring After Resection in Gastric Cancer
- Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
- NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
- Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
- Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization
- Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
- Perioperative Cadonilimab (AK104) in Locally Advanced MSI-H/dMMR Gastric or Gastroesophageal Junction and Colorectal Adenocarcinoma
- Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA
- The Effect of MDT Plus SDM on Survival Benefit of Advanced Gastric Cancer
- Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy
- Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors
- Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System
- Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer
- Selecting Patients Who May Benefit From Immunotherapy by Tissue-based Biomarkers.
- Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
- Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach
- Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
- Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- Laparoscopic Versus Open Lower Mediastinal Lymphadenectomy for Esophagogastric Junction Cancer
- Study on the Effectiveness of Gastroscope Operation Quality Control Based on Artificial Intelligence Technology
- Function Preserving Gastrectomy for T1/2 Gastric Cancer Patients
- Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer
- Dynamic Multiomics Evaluation of Anti-HER2 and Immunotherapy in HER2 Positive Gastric Cancer
- Real World Evidence for the Cycle of Neoadjuvant Chemotherapy in Gastric Cancer With Shared Decision Making
- Verifying the Specificity of a New Method in Predicting Lymph Node Metastasis in Early Gastric Cancer Patients
- Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer
- Laparoscopic Versus Open Gastrectomy for Elderly Local Advanced Gastric Cancer Patients
- Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer
- Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy
- The Origin of Infrapyloric Artery
- MDT to Evaluate the Survival Benefit of Patients With Advanced Gastric / Colorectal Cancer
- Treatment Strategy for Stage IV Gastric Cancer with Positive Peritoneal Cytology As the Only Non-curable Factor
- Liquid Biopsy in Monitoring the Therapeutic Efficacy of Targeted Therapy in Advanced/Metastatic Gastric Cancer
- The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments
- Octreotide LAR as Maintenance Treatment for Patients With NEC
- A Comparison of Laparoscopic With Open Distal Gastrectomy in Advanced Gastric Cancer After Neoadjuvant Chemotherapy
- Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer
- Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer
- Clinical Significance of Circulating Tumor Cells (CTCs) in Blood of Patients With Advanced/Metastatic Gastric Cancer
- A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery
- Sequential HIPEC of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis
- Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
- A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
- LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
- Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
- Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
- A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
- An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
- A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
- A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
- DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
- M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
- AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
- A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
- A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
- A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
- A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
- A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
- A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
- A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
- ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.
- Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
- Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
- Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
- Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
- A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
- A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
- Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
- Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
- Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
- Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
- Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis
- Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
- A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
- A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
- A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma
- A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
- A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer
- A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
- Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
- Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers
- A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
- A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2
- Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
- A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor
- Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
- Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
- Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer
- Incidence of Pancreatic Fistula After Radical Gastrectomy
- A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
- Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
- Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer
- Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
- Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery
- Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer
- A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
- A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
- Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)
- A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
- Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric Cancer
Cancer
Osteosarcoma
骨肉瘤Led 4 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Knockdown of PRDX2 Inhibits the Proliferation, Growth, Migration, Invasion, and MMP9 Activity of Ewing's Sarcoma Cells Cultured In Vitro.
- Regulatory role of PI3K/Akt/WNK1 signal pathway in mouse model of bone cancer pain.
- SNHG9/miR-214-5p/SOX4 feedback loop regulates osteosarcoma progression.
- Primary EWS/PNET of the lung with TP53 germline and SKT11 somatic mutation: A case report and review of the literature.
Earlier papers (2016–2020)6
- KIF18B promotes tumor progression in osteosarcoma by activating β-catenin.
- The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
- Construction of Anti-hPD-L1 HCAb Nb6 and in Situ 124I Labeling for Noninvasive Detection of PD-L1 Expression in Human Bone Sarcoma.
- Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
- Association between interleukin 8 -251 A/T and +781 C/T polymorphisms and osteosarcoma risk in Chinese population: a case-control study.
- [Deficiencies in the Diagnosis and Treatment of Pulmonary Metastatic Osteosarcoma: A Chinese Multidisciplinary Survey].
All its trials on ClinicalTrials.gov, any status1
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 12 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 2.3%.
23 hospitals in Beijing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingComparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
- Phase
- Phase 2
- Started
- 2025-07
- Registry
- NCT07559864
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingEfficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Registry
- NCT07379047
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led12
- Long-term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial.
- Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies.
- Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China.
- CT features combined with RECIST 1.1 criteria improve progression assessments of sunitinib-treated gastrointestinal stromal tumors.
- Percutaneous ultrasound-guided radiofrequency ablation for patients with liver metastases from gastrointestinal stromal tumors.
- An additional gastrojejunostomy may reduce the incidence of moderate and severe delayed gastric emptying after distal segmental duodenectomy for gastrointestinal stromal tumors.
- Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China.
- Cytoreductive surgery offers prognostic benefits in metastatic gastrointestinal stromal tumors with generalized progression following imatinib therapy: a single institute retrospective study.
- Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study.
- Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study.
- Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study.
- Could computed tomography be used as a surrogate of endoscopic ultrasonography in the screening and surveillance of small gastric Gastrointestinal stromal tumors?
Earlier papers (2016–2020)16
- The current status of and prospects in research regarding gastrointestinal stromal tumors in China.
- A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.
- Heterogeneity of metastatic gastrointestinal stromal tumor on texture analysis: DWI texture as potential biomarker of overall survival.
- [Current status and progress in novel drug research for gastrointestinal stromal tumors].
- Cytoreductive surgery for metastatic gastrointestinal stromal tumors followed by sunitinib compared to followed by imatinib-a multi-center cohort study.
- [Advances in radiological studies of gastrointestinal stromal tumors].
- [To improve the understanding of CD117-negative gastrointestinal stromal tumor].
- MRI in predicting the response of gastrointestinal stromal tumor to targeted therapy: a patient-based multi-parameter study.
- Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
- Non-Gaussian diffusion imaging with a fractional order calculus model to predict response of gastrointestinal stromal tumor to second-line sunitinib therapy.
- Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.
- [Analysis of biological characteristics and prognosis on gastrointestinal stromal tumor with PDGFRA gene mutation].
- Clinical benefit of sunitinib in gastrointestinal stromal tumors with different exon 11 mutation genotypes.
- Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.
- [Molecular mechanism of gastrointestinal stromal tumors and progress in drug research].
- [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
All its trials on ClinicalTrials.gov, any status15
- A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
- Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
- A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment
- Ripretinib in Chinese Patients With Advanced GIST: a Real World Study
- Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
- Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
- A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
- Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients
- A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
- A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
- A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
- Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor
Cancer
Neuroblastoma
神经母细胞瘤Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
24 hospitals in Beijing for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Ewing sarcoma
尤文肉瘤Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
17 hospitals in Beijing for Ewing sarcoma139 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 3 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
15 hospitals in Beijing for multiple myeloma178 hospitals in China for multiple myeloma
No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led3
- miR-34a promotes the immunosuppressive function of multiple myeloma-associated macrophages by dampening the TLR-9 signaling.
- Treg-derived TGF-β1 dampens cGAS-STING signaling to downregulate the expression of class I MHC complex in multiple myeloma.
- Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
13 hospitals in Beijing for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other linked evidence
Getting in touch
Name card to show staff or a driver
北京大学肿瘤医院
Peking University Cancer Hospital
北京
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Peking University Cancer Hospital & Institute; Peking University Cancer Hospital and Institute; Beijing Cancer Hospital and Institute; Beijing Cancer Hospital; Peking University Cancer Hospital Yunnan; Beijing Cancer Hospital & Institute; Peking University Cancer Hospital/Institute; Peking University Cancer Hospital &Institute